Manchester Science Partnerships United Kingdom

Manchester Science Partnerships (MSP) is home to a unique community of scientists, innovators, investors and entrepreneurs and actively supports companies in the science, technology and innovation-driven sectors. Putting collaboration first and providing access to specialist finance, talent, markets, networks and investors enables MSP to support the acceleration of business growth through innovation.  

MSP’s unique partnerships across the science and technology sectors include The University of Manchester, Manchester Metropolitan University, Central Manchester University Hospitals NHS Foundation Trust (CMFT), Manchester City Council, Northern Health Science Alliance, Health Innovation Manchester, N8 and industry bodies such as BioNow and the BIA.

As the UK’s leading science and technology park operator, with five campuses across North West England including Alderley Park in Cheshire, MSP is home to more than 300 high growth businesses and offers  everything from specialist incubation centres to bespoke build laboratories and international centres of R&D excellence.

It is our unique approach and unrivalled connections that enable companies in the MSP community to survive, grow, and thrive better than the local or national average – turning great ideas into commercial reality.

Dr Neil Jones
LinkedIn logo Science Service Manager 


MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

MGB Biopharma Ltd United Kingdom

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.

Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

 MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections. MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Dr Miroslav Ravic
LinkedIn logo CEO 
Mr Raymond Spencer
LinkedIn logo CFO